http://www.cnr.it/ontology/cnr/individuo/prodotto/ID109120

C-Type natriuretic peptide (CNP) and NT-Pro-CNP in Raynaud's phenomenon: disease severity markers? (Abstract in rivista)

Type

Prodotto della ricerca (Classe)
Abstract in rivista (Classe)

Label

C-Type natriuretic peptide (CNP) and NT-Pro-CNP in Raynaud's phenomenon: disease severity markers? (Abstract in rivista) (literal)

Anno

2007-01-01T00:00:00+01:00 (literal)

Alternative label

Del Ry S.; Della Rossa A.; Maltinti M.; Cabiati M.; Vesprini E.; Bazzichi L.; Bombardieri S.; Emdin M.; Giannessi D. (2007)
C-Type natriuretic peptide (CNP) and NT-Pro-CNP in Raynaud's phenomenon: disease severity markers?
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Del Ry S.; Della Rossa A.; Maltinti M.; Cabiati M.; Vesprini E.; Bazzichi L.; Bombardieri S.; Emdin M.; Giannessi D. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

Poster scelto come comunicazione orale (literal)

Convegno

Biochimica Clinica (literal)

Rivista

Biochimica clinica (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

In: Biochimica Clinica, vol. 31 pp. 527 -. Biomedia, 2007. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

Background: C-type natriuretic peptide (CNP) plays a central role in the control of vascular tone as well as in several clinical conditions characterized by endothelial dysfunction. Aim: was to evaluate whether the levels of these peptides are increased in a population of patients affected by Raynaud phenomenon, either primary or secondary to systemic sclerosis. Methods: 30 no-smoker patients have been enrolled to date, 12 affected by systemic sclerosis according to ACR criteria and 18 by primary Raynaud's phenomenon (4 M, 26 F, mean age: 50 years, range: 21-73). Significant co-morbidities, such as hypertension, diabetes, obesity, hypercholesterolemia, renal failure, were ruled out. NT-proCNP, that circulates at higher concentrations than CNP and allows a direct assay and the use of smaller amounts of plasma, was determined in all patients by using a direct ELISA (Biomedica Gruppe-Pantec) while CNP was measured in a subset of patients (n=16) by a specific radioimmunoassay (Phoenix Pharmaceuticals, Belmount, CA, USA) after a preliminary solid phase extraction. All of the patients underwent nailfold capillary microscopy (Scopeman Pico-Charm View, Moritex, 200 x magnification), with a general description and a quantitative capillaroscopic score according to authoritative sources. Statistical analysis was made by non parametric tests and simple regression where appropriate. Results: Plasma levels of NT-proCNP were significantly different between patients with primary Raynaud's phenomenon and patients with Raynaud's phenomenon associated with systemic sclerosis (p=0.04). Moreover, plasma levels of CNP were correlated to capillaroscopic score (R: 0.5 p = 0.03) Conclusions: These preliminary results indicate that plasma levels of CNP rise in parallel with the severity of microangiopathy in Raynaud's phenomenon and that NT-pro CNP plasma levels are significantly higher in scleroderma patients in comparison with primary Raynaud's phenomenon, suggesting that these peptides may represent a valid aid in the early diagnosis of this challenging disorder. Ref.: Sudoh T, et al. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biopys Res Comm. 1990; 168: 863-70. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni